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Due to the importance of fat tissues in both energy balance and in the associated disorders arising when such balance is not
maintained, adipocyte diﬀerentiation has been extensively investigated in order to control and inhibit the enlargement of white
adipose tissue. The ability of a cell to undergo adipocyte diﬀerentiation is one particular feature of all mesenchymal cells. Up
until now, the peroxysome proliferator-activated receptor (PPAR) subtypes appear to be the keys and essential players capable
of inducing and controlling adipocyte diﬀerentiation. In addition, it is now accepted that adipose cells present a broad plasticity
that allows them to diﬀerentiate towards various mesodermal phenotypes. The role of PPARs in such plasticity is reviewed here,
although no deﬁnite conclusion can yet be drawn. Many questions thus remain open concerning the deﬁnition of preadipocytes
and the relative importance of PPARs in comparison to other master factors involved in the other mesodermal phenotypes.
Copyright © 2007 Louis Casteilla et al.Thisisanopen access article distributedunderthe Creative CommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Adipose tissues have long been associated with the invasive
prevalence of obesity and metabolic disorders. Recent ad-
vances have focused the attention on the presence of in-
triguing cells able to diﬀerentiate towards various pheno-
types and recall the old use of fat in plastic and reconstruc-
tive surgery [1–3]. Two rather distinct medical and scientiﬁc
domains share these perspectives but irrespective of ﬁeld, a
good understanding of adipogenesis is absolutely requisite to
manipulating and controlling adipocyte diﬀerentiation. This
point is emphasized by the fact that adipocyte diﬀerentiation
belongs to the mesenchymal stroma or stem cell hallmark.
We thus should consider that any of these cells can acquire
the adipocyte phenotype depending on its environment. In
thisview,peroxysomeproliferator-activatedreceptor(PPAR)
family of transcription factors appears to be a key and un-
avoidable actor.
After a brief overview on adipose tissues, this review will
focus on the importance of PPARs and PPARγ in particular
in adipose-derived cell phenotype and plasticity.
2. ADIPOSE TISSUES: WHAT ROLE DO PPARS PLAY?
2.1. Adiposetissueoradiposetissues?
Three functionally diﬀerent types of adipose tissues are de-
scribed in mammals: brown adipose tissue (BAT), white
adipose tissue (WAT), and bone-marrow adipose tissue
(BMAT) [4–6].
BAT and WAT participate diﬀerently in energy balance
and homeostasis. BAT is heavily involved in nonshivering
thermogenesis (cold and diet-induced thermogenesis). In
contrast, WAT is mainly involved in energy storage and is
now considered an endocrine organ [4–7]. Brown and white
adipocytes similarly display lipogenesis, triglyceride accu-
mulation, and lipolysis, but brown adipocytes are also spe-
cialized in energy dissipation in the form of heat. These
cells are smaller than white adipocytes, contain abundant
mitochondria and highly express the uncoupling protein-
1 (UCP-1) [8]. This protein, by uncoupling ATP synthesis
from the respiratory-chain function, subsequently promotes
the dissipation of energy as heat [9]. It is noteworthy that
only 40%–60% of the whole cell population in BAT as well
as in WAT is composed of mature adipocytes. Endothelial,
haematopoietic cells, and adipocyte precursors, the so-called
preadipocytes, or adipose-derived stromal cells (ASCs) are
also found in adipose tissues [10]. It has long been known
that adipocyte precursors are present throughout adulthood
and can proliferate and/or be recruited depending on physi-
ological or physiopathological situations [7]. BAT and WAT
develop at speciﬁc and diﬀerent locations and WATs various
locations also determine its diﬀerent metabolic and molecu-
lar features [11, 12].2 PPAR Research
In contrast to brown and white adipocytes, the role of
medullar adipocytes has been poorly investigated and is not
well-understood [5]. The number and size of adipocytes
seem to be inversely correlated to haematopoietic activity
in bone marrow based on the physiological or physiopatho-
logical situation. Nevertheless, it is noteworthy that many
scattered adipocytes are observed in active haematopoietic
bone marrow. Highly similar gene expression has been de-
scribedbetweenhumansubcutaneousandmedullarymature
adipocytes, suggesting that medullary adipocytes may share
someofthefunctionsexhibitedbysubcutaneousandvisceral
adipocytes [13].
Beside the physiological anatomy of adipose tissues, ec-
topic location of adipocytes is also observed in degenerative
tissues. The origin of these adipocytes inﬁltrating the degen-
erative tissues is still unclear.
2.2. PPARsandwhiteadipocytedifferentiation
As usual in any diﬀerentiation program, a subtle balance
and interconnection exist between cell cycle and commit-
ment to adipocyte diﬀerentiation. In this context, overex-
pression of both C/EBPα and PPARγ, mediates the cell cy-
cle arrest after clonal expansion. Indeed, PPARγ induces
cell cycle withdrawal by the inhibition of the transcription
factor E2F/DP DNA-binding activity via downregulation of
the protein phosphatase 2A (PP2A) [14]. In the opposite,
E2Fs trigger clonal expansion, and terminal adipocyte dif-
ferentiation through regulation of PPARγ expression [15].
In the same manner, p107 protein belonging to retinoblas-
toma family is also involved in regulating PPARγ and its re-
covery into deﬁcient cells reduces adipocyte diﬀerentiation
through the downregulation of PPARγ activity [16]. The po-
tency of PPARγ and its interplay with cell cycle is illustrated
by a report studying liposarcoma cells. Treating cells from
these aggressive tumours with ligands for both PPARγ and
the retinoid X receptor (RXR) forces their terminal diﬀeren-
tiation [17]. Indeed, the antiproliferative activity of PPARγ is
now investigated to limit and treat tumour cell proliferation
althoughseveralPPARγ ligand-mediatedantiproliferativeef-
fectsactthroughacomplexityofPPARγ-independent mech-
anisms [18]. Nevertheless, this antigrowth eﬀect seems to be
speciﬁc to cell type because PPARγ activation promotes the
proliferation of neural stem cells [19], instead of their diﬀer-
entiation.
The crucial role for PPARγ as a dominant regulator
of white-adipocyte diﬀerentiation is now well documented
and largely reviewed [20, 21]. It interplays with several
other nuclear factors such as CAAT Enhancer Binding Pro-
tein (C/EBP) and Sterol regulatory element-binding proteins
(SREBP) families and numerous coactivators or corepres-
sors. The use of genetic ablated cells demonstrates that while
the lack of C/EBPα can be overcome by the overexpression of
PPARγ, the opposite does not hold true that PPARγ is abso-
lutely required for the adipogenic program [22]. During this
program, the expression of both factors is interdependent
not only in promoting adipocyte diﬀerentiation but also in
sustaining and maintaining the fully diﬀerentiated adipocyte
phenotype. Any signal able to modulate one or the other
of both transcription factors subsequently induces change
in adipocyte diﬀerentiation. Thus, insulin/IGF-I signalling
modulates adipogenesis by the upregulation of PPARγ ex-
pression via the insulin/IGF-I receptor-AktSH2-B-Foxo1-
pathway [23].
Whereas PPARγ was described as a factor involved in
white adipocyte diﬀerentiation, PPARα and δ were described
for their role in fatty acid oxidation in several tissues includ-
ingadiposetissue[24–27].However,gain-of-functionexper-
iments suggest that both PPARδ and PPARγ isoforms are re-
quired to facilitate maximal lipid accumulation and diﬀeren-
tiation during white adipogenesis [28].
As PPARγ stimulates white adipogenesis, its negative
control inhibits this process. In this way, hypoxia-mediated
inhibition of adipogenesis can be partly explained via the
repression of PPARγ expression by the hypoxia-inducible
factor-1 (HIF-1)-regulated gene DEC1/Stra13, a member of
the Drosophila hairy/enhancer of split transcription repres-
sor family. Similarly, the inhibition of adipogenesis by cy-
tokines is mediated via the repression of PPARγ function
through kinase cascade [29, 30]. It has also been demon-
strated that the constitutive expression of GATA-2 and
GATA-3 resulted in a decrease in PPARγ expression and a
consequent inhibition of adipocyte diﬀerentiation [31].
2.3. Preadipocytes,circulatingcells,andPPARs
Theﬁrstreportinthisﬁeldwaspublishedin2005.Itsauthors
described a circulating human cell population able to diﬀer-
entiate towards adipocytes when cultured under adipogenic
conditions. Moreover, these human progenitors engrafted
and formed adipose tissue following injection into SCID
mice[32].Thisreportisnowsupportedbyarecentinvestiga-
tion suggesting that new fat cells arise not only from resident
precursor cells within the tissue, but also from other sources,
such as BM-derived circulating progenitor cells. One diﬀer-
ence between both reports is the nature of the newly-formed
adipocytes. In the ﬁrst study, unilocular white adipocytes
were observed whereas in the second, mutlilocular cells, ex-
pressing low levels of UCP1, were detected. In this work,
the appearance of bone-marrow-derived adipocytes in the
fat pad is triggered by PPARγ ligand [33]. No explanation
is proposed for this eﬀect of PPARγ ligand, although it ap-
pears to be at least partly a speciﬁc mechanism because this
phenomenon is not totally reproduced by a high fat diet.
Obviously, the underlined mechanisms and the relevance
of such observations need further investigation, but could
participate in the ectopic emergence of fat cells through
the local recruitment of circulating adipocyte progenitor
cells.
2.4. RoleofPPARsinwhiteandbrownadipocytes
Therelationshipbetweenbrownandwhitefatiscomplexbe-
cause besides the typical interscapular brown adipose tissue,
anextensiveanalysisofthediﬀerentfatdepositsrevealedthatLouis Casteilla et al. 3
scattered brown adipocytes are present in any white adipose
depot also in primates [34, 35]. Furthermore, brown fat can
extensively change into white-like fat and conversely, accord-
ing to physiological or physiopathological situations and the
species [36]. These properties led us to use the term “plas-
ticity of adipose tissue.” The main pitfall is that a lack of un-
coupling protein-1 (UCP-1) expression is taken as the gold
standard for white fat and no positive marker is yet char-
acterized to clearly identify white adipose phenotype. Thus,
with the present knowledge, it is not possible to determine
whether brown adipocytes can be transformed into white-
like adipocytes with diﬀerent metabolic properties (termed
masked brown adipocyte) or into true white fat cells. The es-
tablishment of diﬀerent preadipocyte cell lines and the use of
primary culture favor the existence of distinct precursor cells
[4]. First depending upon the origin of cultured cells (i.e.,
from brown or white fat) a corresponding brown or white
mature phenotype is obtained [37]. Second, genetic manip-
ulations allowing irreversible labelling of brown adipocytes
show that they do not convert into white adipocytes dur-
ing normal mouse development [38]. Third, no diﬀerenti-
ation of pluripotent mouse embryonic stem cells into brown
adipocytes even after PPARγ activation take place whereas
white phenotype can be easily obtained [39]. In this regard,
it is noteworthy that brown adipocyte is the only cell type
that coexpresses high levels of the three PPAR subtypes. Fur-
thermore, PPARα and PPARγ are strictly subjected to oppo-
site regulation by retinoids in brown fat, supporting the no-
tion of speciﬁc physiological roles of each transcription fac-
tor in controlling brown fat diﬀerentiation and thermogenic
activity [40]. A further step was undertaken when PGC-1,
for PPARγ coactivator 1, was identiﬁed in brown fat. Ini-
tially claimed as a speciﬁc factor to brown fat, it was pro-
posed to be a coactivator involved in brown versus white
adipocyte diﬀerentiation. This coactivator has been shown
to control a subset of genes involved in mitochondrial ac-
tivity and biogenesis [21, 41]. This is consistent with the
adenovirus-mediated expression of human PGC-1α that in-
creases the expression of UCP1, respiratory chain proteins,
andfattyacidoxidationenzymesinhumanadipocytesdiﬀer-
entiated in primary culture [42]. Nevertheless it appears that
this protein displays numerous functions in many tissues, all
ofthemrelatedtomitochondrialfunction[43].Otherfactors
havebeen proposed tobe centralswitchesforwhitetobrown
adipocyte diﬀerentiation, including the retinoblastoma pro-
tein [44] and the corepressor RIP140 [45].
3. PPARS AND MESODERMAL FATES
Although, it is well admitted that adipose cells arise from
mesodermal origin, the exact origin of adipocyte precursors
is not well deﬁned as illustrated by the recent work on circu-
lating adipose precursors [32]. Recently, it appears that cells
named previously preadipocytes can diﬀerentiate towards
v a r i o u sm e s o d e r m a lo r i g i n s[ 46–48]. These cells were thus
named adipose derived stromal cells (ADSC). Conversely,
it seems thatadipocyte phenotype could be obtained from
diﬀerent cells including myoblasts [49]. PPARs may thus be
involved in the preferential cell commitment towards one or
the other lineage and/or in maintaining pluripotency. These
aspects are discussed in the second part of this review.
3.1. Adipocyteversusosteogenicpotential
Many reports have demonstrated that adipocytes and os-
teoblasts share a common precursor. Osteoblastic genes are
expressed in cell lines able to diﬀerentiate towards adipocyte.
Bipotent cells with features speciﬁc to both osteoblasts and
preadipose cells have been cloned from bone marrow [50]
and more recently from human adipose tissue [47, 48, 51,
52]. Recently, Birk et al. have shown that the 3T3-F442A
preadipocyte clonal cell line diﬀerentiate into osteoblasts
[53]. It has also been reported that stromal colonies, either
undiﬀerentiated or diﬀerentiated into matureadipocytes, are
able to give rise to osteogenic cells when transplanted in in-
traperitonealdiﬀusionchambers.Theseobservationssuggest
that stromal cells, ﬁrst diﬀerentiated along the adipogenic
lineage, are able to dediﬀerentiate and then to rediﬀerentiate
in an osteoblastic phenotype.
Several transcription factors, such as PPARγ and Runx2,
have been proposed as playing a critical role in the commit-
ment of bipotent stem cells towards the adipogenic or the os-
teogeniclineages[54].However,ithastobenotedthattheef-
fect of genes of interest are often investigated in diﬀerent cell
lines already committed in either one or the other lineage,
making dubious their role in the regulation of the commit-
ment of a multipotent stem cell. For example, ectopic over-
expressionofadipogenictranscriptionfactorssuchasPPARγ
induces transdiﬀerentiation of mouse osteoblastic MC3T3-
E1 cells into mature adipocytes [55]. A unique investigation
really addressed the issue of the commitment of stem cells on
embryonic stem (ES) cells. In this report, the authors tran-
siently suppressed PPARγ expression. This genetic manip-
ulation directs ES cells into an osteoblastic lineage suggest-
ing that PPARγ can be considered a proadipogenic as well as
an anti-osteoblastic factor [56]. The role of the transcription
factordeltaFosBhasbeeninvestigatedinfurtherdetail.Over-
expression of deltaFosB under the control of a promoter-
driving transgene both in osteoblasts and adipocytes led to
increased bone mass and decreased adipocyte formation.
Given the assumption of a reciprocal development of both
lineages, it has been proposed that diﬀerentiation into one
cell type could be a consequence of the action of deltaFosB
in the other [57]. More recently, elegant experiments from
the same group generating transgenic mice that express
deltaFosB in a bone-speciﬁc manner, led the authors to con-
clude that the change in osteoblast and adipocyte diﬀeren-
tiation results from independent cell-autonomous mecha-
nisms [58]. Therefore, factors playing a role in the switch
of stem-cell diﬀerentiation towards the adipogenic or os-
teogenic lineages remain to be deﬁnitively identiﬁed. The 14-
3-3-binding protein, TAZ (transcriptional coactivator with
PDZ-binding motif), which coactivates Runx2-dependent
gene transcription while repressing PPARγ-dependent gene
transcription could be also involved [59].4 PPAR Research
3.2. MyoblastandPreadipocyte
The deciphering and understanding of myogenesis is far be-
yond our current understanding of adipogenesis, but both
programs are closely linked by their mesodermal origin and
the well-described emergence of adipocytes in denervated
muscle. From such observations, the question of a putative
role of PPARs in directing cell fate towards one of the dif-
ferentiation programs seems reasonable. As described for ﬁ-
broblasts, overexpression of PPARγ or activation through its
ligands in satellite cells transdiﬀerentiates myoblasts towards
the adipogenic phenotype. This characteristic is shared by
the other key adipogenic factor, C/EBPα [60]. This transdif-
ferentiation was observed for myoblasts in all mammals and
during the whole development [49]. In addition, the activa-
tion of PPARδ abolishes the development of multinucleated
myotubeswhileinducingtheexpressionofPPARγ gene.Loss
and gain function experiments are consistent with a role for
PPARδ as an inducer of transdiﬀerentiation into adipocyte-
likecells,whichprecedesandtriggersPPARγ expression[61].
Ontheotherhand,PPARγ canbecontr olledbyWntpr o-
teinsandespeciallyWnt1andWnt-10bthatgovernadipoge-
nesis.Indeed,PPARγaswellasC/EBPproteinsisinhibitedby
Wnt signalling, which in turn maintains preadipocytes in an
undiﬀerentiatedstate.WhenWntsignallinginpreadipocytes
is prevented by the overexpression of Axin or dominant-
negative T-Cell Factor-4 (TCF4), these cells diﬀerentiate into
adipocytes. These results are strengthened by the fact that
the lack of Wnt signalling also induces transdiﬀerentiation
of myoblasts into adipocytes [62]. However, the relation-
ship between Wnt signalling and PPARγ seems to be com-
plex because the impairment or activation of Glycogen Syn-
thase Kinase-3β (GSK3β)/β-catenin only aﬀects a subset of
PPARγ-dependent genes [63].
Finally, it has been suggested that myostatin, a potent
negative regulator of skeletal muscle growth member of
the transforming growth factor beta (TGF-β) family, blocks
adipocyte diﬀerentiation via down regulation of PPARγ in
3T3-L1 [64]. However, recent data reports that in pluripo-
tent C3H10T1/2 cell line, myostatin treatment may promote
the diﬀerentiation of multipotent mesenchymal cells into the
adipogenic lineage and inhibit myogenesis [65, 66].
3.3. Preadipocytesandmacrophages
Analysis of the literature lined out that adipocyte and
monocyte/macrophage lineages have many features in com-
mon including aP2 and PPAR expression. More surpris-
ingly, we demonstrated that preadipocytes eﬃciently phago-
cytoze yeasts and apoptotic bodies in a similar manner,
albeit to a lesser extent, than specialized phagocytic cells
such as macrophages [67, 68]. This suggests the involve-
ment of adipocyte progenitors in tissue remodelling and
plasticity through the discarding of apoptotic bodies. A
proﬁling analysis between adipocyte and macrophage lin-
eages expanded the known similarities between these cell
phenotypes [69]. Finally, preadipocytes can be very rapidly
converted into macrophage-like cells when injected into
the peritoneal cavity, considered a likely environment for
supporting macrophage phenotype [69]. The rapidkinet-
ics of change suggests a transdiﬀerentiation process and/or
a stronger lineage relationship between adipocyte progeni-
tors and macrophages than expected. Since only 80% of the
macrophages come from bone marrow in obesity [70], one
could thus postulate that the remaining 20% of adipose-
tissue-resident macrophages derive from preadipocytes. Ac-
cording to the importance of PPARγ to direct cells towards
adipocyte diﬀerentiation, it is reasonable to wonder if PPARs
could be involved in such plasticity.
PPARγ isexpressedatlowlevelsincirculatingmonocytes
anditsexpressionincreasessigniﬁcantlyupondiﬀerentiation
to macrophages, including in the foam cells of atheroscle-
rotic lesions. Numerous studies have thus focused on its role
in macrophage metabolism and activation and its possible
involvement in the process of atherosclerosis. These stud-
ies have provided evidence supporting a role of PPARγ in
both lipid uptake and lipid eﬄux pathways in macrophages
[71]. The fact that PPARγ could inﬂuence both lipid uptake
and eﬄux raised the question of whether the net eﬀect of
PPARγ ligands on macrophages within an atherosclerotic le-
sion would be to promote or impede foam cell formation.
PPARγ is not essential for myeloid development or for ma-
turemacrophagefunctions,suchasphagocytosisandinﬂam-
matory cytokine production [72]. It is also a negative regula-
tor of macrophage activation and inhibits macrophage pro-
duction of inﬂammatory cytokines, although some of this
activity may not be mediated by PPARγ [73]. In addition,
PPARγ agonists inhibit foam-cell formation in vivo [74].
However, such an eﬀect could be cell-type dependent [75].
Although PPARγ seems fundamental in preadipocyte and
macrophage biology, adipocytes and foam cells are probably
distinct cell types and thus far no study has described a po-
tential role of PPARγ in the diﬀerentiation of preadipocytes
into macrophage-like cells.
4. CONCLUSION
The importance and the role of PPARs in adipogenic process
is deﬁnitively demonstrated and brought numerous new in-
sights in our understanding of adipogenesis but many ques-
tionsremainopenconcerningthedeﬁnitionofpreadipocytes
and the relative importance of PPARs compared to other
master genes involved in other mesodermal phenotypes.
Altogether, the negative regulation of several master pro-
teins involved in other mesodermal diﬀerentiation programs
suggests that at least PPARγ can play its role only when
all negative regulators are missing. This could suggest that
preadipocyte status results from a default pathway.
Similarly, the tissue origin of preadipocytes is now chal-
lenged and needs to be clariﬁed because it can help to build
a more dynamic view of adipose tissue development and the
role of PPAR proteins.
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